I would think management chose to release the good news about their breast cancer "data" a few days before their conference call for a reason. Certainly, as a result of Monday's 23 million shares that traded, their audience for the conference call will be much, much larger. Why would they want a much larger audience if they had bad news to convey? They wouldn't. That's why I think they have more good news that will only boost the price of the stock. With target prices ranging from $9 to $22, this is a great opportunity to buy below $7!
That makes lots of sense. Here's to hoping that there is some great news coming out of this call on Thursday.
The data speaks for itself....and is only addressing two cancers thus far. Ganetespib may be useful as a synergistic treatment for a number of different cancers. Good news tomorrow should push us WAY higher.
Good luck longs!